文献速递白血病

低频TP53热点突变通过克隆扩增导致急性髓系白血病化疗耐药

Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2020-01-27

该研究探讨低频TP53突变在急性髓系白血病(AML)化疗耐药中的作用。TCGA数据分析显示约3%的AML患者可检测到低频TP53突变,且预后较TP53野生型患者差。体外实验表明低频TP53突变克隆具有化疗耐药潜力和白血病干细胞标志物阳性细胞比例增高,并且Romidepsin可重新激活p53靶基因并优先靶向TP53突变亚群。

要点

  • 约3%的AML患者可检测到低频TP53突变,且预后较TP53野生型差。
  • 低频TP53突变克隆具有化疗耐药潜力和白血病干细胞标志物阳性细胞比例增高。
  • Romidepsin可重新激活p53靶基因并优先靶向TP53突变亚群。

核心结论

  • 低频TP53热点突变与AML化疗耐药相关,并提示靶向TP53突变亚群的治疗策略。

研究设计与样本

  • 基于TCGA AML患者测序数据分析低频TP53突变频率及预后。
  • 使用OCI-AML2和MV4-11两株AML细胞系研究低频TP53突变的功能效应。

主要发现

  • TCGA AML数据中约3%的患者可检测到低频TP53突变,且预后较TP53野生型患者差。
  • OCI-AML2和MV4-11细胞均携带低频单热点TP53突变,耐药细胞中TP53突变为均一性。
  • 从亲本细胞分离的TP53突变克隆化疗耐药潜力增加,白血病干细胞标志物阳性细胞比例更高。
  • TP53突变细胞与TP53野生型细胞混合时显示生存优势。
  • Romidepsin可重新激活TP53突变细胞中失调的p53靶基因,并优先靶向TP53突变亚群。

临床怎么用

  • 对AML患者应关注低频TP53突变的检测,其与化疗耐药和不良预后相关。
  • Romidepsin可能通过重新激活p53靶基因和靶向TP53突变亚群来克服化疗耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TP53 mutations (TP53mut) in AML patients associate with poor prognosis that may affect therapy and outcome. In addition to TP53 mut patients, TCGA AML patient sequencing data show that there are around 3% of patients have detectable low-frequency TP53mut reads. Importantly, these patients showed worse outcome as compared with the TP53 wild type (TP53wt) patients. We have studied the effect of low-frequency TP53mut in two AML cell lines, OCI-AML2 and MV4-11. Both cells have low-frequency single hotspot TP53mut. Interestingly, the resistant cells derived from both lines have homogeneous TP53mut. TP53mut clones isolated from the parental cells also show increased chemoresistance potential and have higher population of leukemia stem cell (LSC) maker positive cells, a characteristic of chemoresistant cells. When mixed with TP53wt cells, the TP53mut cells show survival advantage suggesting its potential to develop chemoresistance. We previously showed that histone deacetylase inhibitor Romidepsin can re-sensitize chemoresistant cells by eradicating LSC marker positive cells. Here we further show that Romidepsin can reactivate p53 targeted genes which are dysregulated in TP53mut cells and preferentially targets TP53mut subpopulation. Therefore, our study shows that low-frequency TP53mut is linked to chemoresistance and sheds light on therapeutic strategies for treatments on chemoresistance.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Yan B, Chen Q, Xu J, et al. Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia. Leukemia. 2020. PMID: 31988438. doi:10.1038/s41375-020-0710-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。